Introduction
============

The AMPA class of glutamate-gated ion channel receptors (GluR) are impermeable to calcium if a GluR2 subunit is present in the tetrameric receptor ([@b14]; [@b41]). This impermeability to calcium results from RNA editing of the *GluR2* transcript. The enzyme that catalyses this RNA editing event is a member of the family of [a]{.ul}denosine [d]{.ul}e[a]{.ul}minases that act on [R]{.ul}NA (ADARs). ADAR2 specifically deaminates an adenosine residue in a glutamine (Q) codon to an inosine that is read as guanosine by reverse transcriptase and the translational machinery. ADAR2 converts the glutamine (Q) codon to an arginine (R) codon with 100% efficiency at the *GluR2* Q/R site changing a key residue in the ion channel pore and rendering AMPA receptors assembled with this subunit impermeable to calcium ([@b39]). The editing event also regulates AMPA receptor assembly, slowing the passage of the GluR2 subunit through the ER thus ensuring correct receptor assembly ([@b10]). Failure of RNA editing at this site can lead to neuronal cell death due to the influx of calcium ([@b12]). A decrease in editing at this site has been reported in sporadic ALS motor neurons ([@b16]) and in hippocampal neurons following transient forebrain ischaemia in a rat model of stroke ([@b29]).

Mice that are null mutants for ADAR2 are seizure-prone and die within 3 weeks after birth ([@b12]). Lethality in these *Adar2*^−/−^ mice can be rescued by knocking-in the edited isoform of GluR2 (*GluR2*^*R*^). This experiment suggests that despite ADAR2 having other transcripts that it edits, the critical site is the Q/R site in *GluR2* transcripts. These rescued mice have a normal phenotype, suggesting that the unedited GluR2 isoform does not have an essential biological function.

For this deamination event to occur, ADAR2 must recognize and bind to double-stranded (ds)RNA that is formed at the editing site between the edited exon and the downstream intron ([@b13]). Identified transcripts edited specifically by ADAR2 are mostly expressed in the CNS even though the protein is also expressed in other tissues. RNA editing occurs before splicing and ADAR2 localizes to the nucleus. In some cells, ADAR2 accumulates within the nucleolus ([@b7]; [@b38]); however, this localization is dynamic. When transcripts that can be edited are overexpressed in these cells, ADAR2 relocalizes to the nucleoplasm ([@b7]).

Until now the only regulator found to influence ADAR2 expression is CREB, which can induce ADAR2 expression in hippocampal CA1 neurons in rat brain ([@b29]). In this study, we demonstrate that ADAR2 is dynamically regulated post-translationally by the phosphorylation-dependent peptidyl-prolyl *cis*/*trans* isomerase Pin1 ([p]{.ul}eptidyl-prolyl [i]{.ul}somerase [*N*]{.ul}IMA interacting protein [1]{.ul}). Pin1 binds to a phosphorylated serine or threonine residue preceding a proline residue and catalyses the *cis*/*trans* isomerization of the peptide bond ([@b24]). This conformational change can have a range of consequences on the function of target proteins, altering catalytic activity, stability or subcellular localization (for review see [@b22]). Pin1 binds to the amino-terminus of ADAR2 in a phosphorylation-dependent manner. In the absence of Pin1, ADAR2 protein is more labile and is mislocalized to the cytoplasm, where it is unable to edit pre-mRNAs and there is a decrease in editing of the Q/R and R/G sites in endogenous *GluR2* transcripts. Pin1 is therefore a positive regulator of ADAR2 editing activity.

We also identify a negative regulator of ADAR2 activity, which is WWP2; a HECT (homologous to the E6-AP C terminus) E3 ubiquitin ligase ([@b30]). WWP2 binds to a conserved PPxY motif in ADAR2 and this interaction results in ubiquitination and subsequent degradation of ADAR2. An increase in the expression of WWP2 results in a decrease in ADAR2 protein level. This report of the post-translational regulation of ADAR2 demonstrates how RNA editing activity is controlled by coordinate action of two regulators.

Results
=======

Phosphorylation sites near the N-terminus of ADAR2
--------------------------------------------------

When human ADAR2 was purified to homogeneity from HeLa cells, enzymatic activity was very labile ([@b27]). However, recombinant human ADAR2 protein purified after overexpression in the yeast *Pichia pastoris* is active and stable. To determine if the protein is regulated by post-translational modification, we performed mass spectrometry on recombinant ADAR2 purified from *P. pastoris* and identified two phosphorylated serines near the amino-terminus, serine (S) 26 and S31 ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}). Phosphorylation at S26 has been independently verified ([@b6]). The amino-terminal region of ADAR2 is of interest since it has been shown to be important for dimerization of the protein and autoinhibition of catalytic activity ([@b9]; [@b25]).

ADAR2 interacts with Pin1
-------------------------

The phosphorylated residues near the N-terminus of ADAR2 are within potential recognition motifs (Ser/Thr-Pro) for the phosphorylation-dependent peptidyl-prolyl *cis*/*trans* isomerase Pin1, a well-conserved and extremely efficient enzyme for transducing post-translational modifications into conformational changes in key cellular proteins ([@b22]). To determine whether Pin1 interacts with ADAR2, HEK293T cells were transiently transfected with a construct expressing ADAR2 bearing a FLAG epitope tag at the N-terminus and tetra-His tag at the C-terminus. After 24 h, the cells were harvested, whole cell protein extracts were immunoprecipitated with anti-FLAG monoclonal antibody and analysed by immunoblot detection of the immunoprecipitate with mouse anti-mitotic phosphoprotein monoclonal-2 (MPM-2) antibody ([@b5]), that recognizes the phosphorylated Pin1 motif (Ser/Thr-Pro) in proteins. As shown in [Figure 1A](#f1){ref-type="fig"}, α-MPM-2 recognizes the FLAG-tagged ADAR2 protein. We mutated T32, as this is the residue that precedes the proline so it may be important for Pin1 binding. When the immunoprecipitation was repeated with alanine (A) substitutions for S26, S26/31 or T32 at the amino-terminus, the antibody recognized ADAR2 less efficiently and loss of binding of the MPM-2 antibody was particularly evident with the triple mutant ADAR2^S26A/S31A/T32A^ ([Figure 1A](#f1){ref-type="fig"}), suggesting that the amino-terminus of ADAR2 harbours phosphorylated S/T-P sites at the amino-terminus that are likely to bind Pin1.

The ability of ADAR2 to bind to Pin1 was next evaluated by *in vitro* binding assays with GST--Pin1 and recombinant ADAR2 purified from *P. pastoris.* As shown in [Figure 1B](#f1){ref-type="fig"} (left panel), ADAR2 binds strongly to GST--Pin1 whereas ADAR2 did not interact with the GST beads alone. To map the interaction between Pin1 and ADAR2, ADAR2^S26A^, ADAR2^S26A/S31A/T32A^ or an N-terminal deletion of ADAR2 from amino acid to 4--72 ([@b42]) were purified from *P. pastoris* ([Figure 1B](#f1){ref-type="fig"}, right panel) and similarly tested for interaction with GST--Pin1. The interaction of GST--Pin1 with ADAR^S26A^ was slightly weaker than with wild-type ADAR2 and interaction was drastically decreased with the triple mutant ADAR2^S26A/S31A/T32A^, and totally absent with ADAR2^Δ4--72^ ([Figure 1B](#f1){ref-type="fig"}, left panel). To determine if the interaction with Pin1 depends on ADAR2 phosphorylation, a transient transfection of ADAR2 into HEK293T cells was performed and the lysate was treated with λ phosphatase followed by a pull-down assay with GST--Pin1 beads. The interaction between ADAR2 and Pin1 was observed and this was abolished with a longer λ phosphatase treatment ([Figure 1C](#f1){ref-type="fig"}).

As these experiments were performed *in vitro*, we then analysed the Pin1 ADAR2 interaction in HEK293T cells by transiently cotransfecting with constructs expressing FLAG-tagged ADAR2 and HA-tagged Pin1. The cells were harvested after 24 h and an immunoprecipitation of the lysate was performed with anti-FLAG monoclonal antibody and the precipitate was detected on an immunoblot with an anti-HA antibody ([Figure 1D](#f1){ref-type="fig"}). Only the wild-type ADAR2 interacted with HA-tagged Pin1. Neither the triple alanine mutant nor ADAR2^Δ4--72^ interacted with Pin1. In addition, ADAR2 that has mutations in both RNA-binding domains and cannot bind to dsRNA (ADAR2^RRM1--2^) ([@b40]) does not interact with Pin1. Therefore, ADAR2 has to bind to RNA before it can interact with Pin1. In the *in vitro* binding assays with GST--Pin1 and recombinant ADAR2 purified from *P. pastoris* ([Figure 1B](#f1){ref-type="fig"}), ADAR2 appears to interact with GST--Pin1 in the absence of dsRNA. However in our experience, it is difficult to eliminate all the dsRNA present in the purified protein fraction from yeast ([@b9]) so therefore we presume that this *in vitro* reaction is also mediated by dsRNA. Similar results were obtained when HEK293T cells were transiently transfected with FLAG--ADAR2 followed by coimmunoprecipitation with endogenous Pin1 ([Figure 1E](#f1){ref-type="fig"}). These results demonstrate that Pin1 binds to ADAR2 in a phosphorylation-dependent manner and that this interaction occurs at the amino-terminal of ADAR2 after it has bound to RNA.

Pin1 expression is required for optimal editing at the GluR2 Q/R site
---------------------------------------------------------------------

Since ADAR2 converts a glutamine (Q) codon to an arginine (R) codon with 100% efficiency at the *GluR2* Q/R site in neurons, the important question is whether the interaction between Pin1 and ADAR2 affects editing activity at the critical *GluR2* Q/R site. To address this point, we analysed editing of the *GluR2* Q/R site in HeLa cells. To increase the level of editing at the Q/R site by ADAR2 in HeLa cells, we transiently cotransfected a plasmid encoding ADAR2 with the *GluR2 B13* minigene. The level of editing rose to 100%. We then cotransfected an siRNA specific for *Pin1* and editing fell to 53% ([Figure 2A](#f2){ref-type="fig"}).

We also analysed editing at the Q/R site in the *GluR2 B13* minigene transcript ([@b13]) by endogenous ADAR2 and observed it was 60% efficient in this cell line; however, when siRNA specific for *Pin1* was cotransfected, the level of editing fell to 46% ([Figure 2B](#f2){ref-type="fig"}). Editing was restored to 74% when *Pin1* was overexpressed in HeLa cells.

We also examined the effect of reducing Pin1 expression on editing of endogenously expressed *GluR2* transcript in a neuroblastoma cell line, SH-SY5Y ([Figure 2C](#f2){ref-type="fig"}). In this cell line, ADAR2 was cotransfected with either a *Pin1*-specific siRNA or a control siRNA and editing of the endogenous *GluR2* transcript was analysed. Again the level of editing dropped from 100% to ∼60% at the Q/R site when there was a reduction in Pin1 expression. We also analysed editing at the R/G site in the *GluR2* transcript and found it was 69% but dropped to 45% when siRNA specific for *Pin1* was cotransfected whereas editing was 73% when a control siRNA was cotransfected. The reduction in Pin1 expression for this experiment is shown in [Supplementary Figure S2](#S1){ref-type="supplementary-material"}.

To examine the effect of complete Pin1 elimination, we cotransfected constructs expressing the *GluR2 B13* minigene and ADAR2 into an immortalized mouse fibroblast cell line derived from *Pin1*^−/−^ mice ([Figure 2D](#f2){ref-type="fig"}) ([@b8]). The editing activity at the Q/R site was ∼50% and increased to 100% when a construct expressing Pin1 was reintroduced in these cells. All these experiments strongly suggest that ADAR2 requires Pin1 for maximal editing of the critical Q/Rand R/G sites in *GluR2* transcripts.

Pin1 has a role in the nuclear localization of ADAR2
----------------------------------------------------

Pin1 has many diverse activities within the cell and it can alter the cellular localization of its substrate, as occurs with β-catenin ([@b36]). Although ADAR2 has been documented as nuclear, recent evidence demonstrated that in human motor neurons in spinal cord sections, ADAR2 is both nuclear and cytoplasmic ([@b1]). Interestingly, a deletion of the amino-terminal residues 4--72 renders ADAR2 cytoplasmic ([@b42]) and it has also been demonstrated that this region is required for nuclear localization as it contains a non-canonical NLS within the first 64 amino acids ([@b7]). As this deletion removes the Pin1-binding site, we wondered if preventing Pin1 binding also leads to mislocalization of ADAR2. To elucidate this we transiently transfected GFP-tagged ADAR2 into *Pin1*^+/+^ and *Pin1*^−/−^ MEF cells and performed immunofluorescence detection of ADAR2 ([Figure 3A](#f3){ref-type="fig"}). In the absence of Pin1, wild-type ADAR2 is mislocalized in the cytoplasm ([Figure 3A](#f3){ref-type="fig"}, lower panel). Mislocalization of ADAR2 is confirmed when nuclear and cytoplasmic fractionation is performed on *Pin1*^−/−^ MEF cells transiently transfected with FLAG-tagged ADAR2 ([Figure 3D](#f3){ref-type="fig"}). When Pin1 was reintroduced into these cells, the level of ADAR2 in the cytoplasm was significantly reduced ([Figure 3B and D](#f3){ref-type="fig"}). This effect of Pin1 on the localization of ADAR2 requires Pin1 prolyl-isomerase enzymatic activity as a Pin1^S67E^ mutant that is catalytically inactive was unable to restore ADAR2 localization to the nucleus ([Figure 3C](#f3){ref-type="fig"}). GFP--ADAR2 is localized to the nucleus when Pin1 is present; however, cytoplasmic localization of GFP--ADAR2 increases following cotransfection with catalytically inactive Pin1. Increased FLAG--ADAR2 is also observed in the cytoplasmic fraction of *Pin1*^−/−^ MEF cells transiently transfected with FLAG-tagged ADAR2 ([Figure 3D](#f3){ref-type="fig"}).

As Pin1 recognizes a phosphorylated serine or threonine preceding a proline, we replaced the phosphorylated amino acids as well as the prolines with alanine to determine if all were required for nuclear localization. As expected, the triple mutant FLAG--ADAR2^S26/S31A/T32A^ was present in the cytoplasm ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}) and this appears slightly different to ADAR2^Δ4--72^ that is more localized around the nuclear periphery ([Supplementary Figure S4](#S1){ref-type="supplementary-material"}). When the proline mutants were generated; FLAG--ADAR2^P27A^ and FLAG--ADAR2^P33A^, were transiently transfected into HeLa cells together with HA--Pin1 ([Figure 4](#f4){ref-type="fig"}), FLAG--ADAR2^P33A^ was present in the cytoplasm as detected by immunofluorescence as well as by nuclear and cytoplasmic fractionation ([Figure 4B and C](#f4){ref-type="fig"}) whereas FLAG--ADAR2^P27A^ is nuclear. This implies that the second proline is the critical one, thus the phosphorylation of T32 may be the critical site for Pin1 binding and P33 for isomerization. Notably, this is also the most conserved Pin1 site in vertebrate ADAR2 sequences ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}).

Pin1 stabilizes ADAR2
---------------------

We wanted to elucidate if Pin1 had other effects on ADAR2. As Pin1 has been shown to influence the stability of proteins such as β-catenin ([@b36]), NF-κB ([@b37]) and p53 ([@b46]; [@b47]), we wondered if Pin1 also influences the stability of ADAR2. The level of Pin1 was reduced in HeLa cells by transfecting either pSuper *Pin1* siRNA ([@b35]) or a control pSuper *LacZ* siRNA so that the level of endogenous ADAR2 could be analysed ([Figure 5A](#f5){ref-type="fig"}). A similar experiment was performed in the neuroblastoma cell line SH-SY5Y ([Figure 5C](#f5){ref-type="fig"}). Twenty-four hours after transfection, cycloheximide was added to prevent further protein synthesis, a time course from 0 to 8 h was performed to chase the decay of ADAR2 protein and the samples were analysed by immunoblot analysis to determine ADAR2 levels. In both cell lines, the protein level of ADAR2 decreased when cycloheximide was added; however, the decrease was more dramatic when *Pin1* expression was reduced ([Figure 5A--C](#f5){ref-type="fig"}). The stability of the triple mutant ADAR2^S26A/S31A/T32A^ was also analysed after cycloheximide treatment ([Figure 5D](#f5){ref-type="fig"}). As predicted this mutant protein was unstable as it could no longer interact with Pin1. Therefore, Pin1 affects the stability of ADAR2.

The E3 ubiquitin ligase WWP2 interacts with ADAR2
-------------------------------------------------

Mass spectrometry was performed on the original samples of ADAR2 purified from large quantities of HeLa cell nuclear fractions ([@b27]) and one of the proteins that copurified with ADAR2 was WWP2, an E3 ubiquitin ligase containing four WW domains as well as a HECT domain. As ADAR2 was unstable in the absence of Pin1, we wondered if this E3 ligase was involved. WWP2 can bind directly to a PPxY motif within its substrate. Analysis of the ADAR2 amino-acid sequence revealed that this motif was present twice, at the amino-terminus and carboxyl-terminus of ADAR2 and was highly conserved ([Supplementary Figure S5](#S1){ref-type="supplementary-material"}).

To demonstrate that ADAR2 and WWP2 interact, HEK293T cells were transiently cotransfected with constructs expressing FLAG--ADAR2 and WWP2 with a c-myc epitope tag at its amino-terminus. An immunoprecipitation was performed with anti-FLAG monoclonal antibody to precipitate FLAG--ADAR2 and c-myc--WWP2 was present in this precipitate ([Figure 6A](#f6){ref-type="fig"}). To determine which motif in ADAR2 WWP2 binds to, transient transfections were performed in HEK293T cells with constructs expressing full-length and truncated forms of ADAR2 all with FLAG epitope at their amino-terminus. Immunoprecipitation with anti-FLAG monoclonal antibody followed by immunoblot detection with an anti-WWP2 antibody showed that endogenous WWP2 interacts best with full-length ADAR2 and with a truncated protein containing the amino-terminus of ADAR2 ([Figure 6B](#f6){ref-type="fig"}). The interaction of WWP2 with ADAR2 appears to be weaker with the site in the deaminase domain or when the amino-terminus of ADAR2 was deleted. We repeated this immunoprecipitation with anti-FLAG with mutants of ADAR2 in which the binding site for WWP2 in the amino-terminus, carboxyl-terminus or a combination of both binding sites were mutated ([Figure 6C](#f6){ref-type="fig"}). The single mutants decrease the interaction between ADAR2 and WWP2 whereas the interaction was completely abolished with the double mutant.

When a cotransfection was performed in HeLa cells with a constant amount of a plasmid encoding ADAR2 and an increase in the plasmid expressing WWP2, a drastic decrease in ADAR2 protein level was observed ([Figure 6D](#f6){ref-type="fig"}). However, when this experiment was repeated with the double ADAR2^--PPxY^ mutant then the level of the mutant protein did not change as it is no longer a substrate for WWP2. These experiments demonstrated that WWP2 can interact with ADAR2 via the PPxY motif present in ADAR2. An increased expression of WWP2 in HeLa cells resulted in a reciprocal decrease in ADAR2 levels; however, the protein level of the ADAR2^--PPxY^ mutant unable to bind WWP2 remained stable, demonstrating that WWP2 can cause a decrease in ADAR2 protein levels.

WWP2 poly-ubiquitinates ADAR2
-----------------------------

To verify that ADAR2 is indeed poly-ubiquinated by WWP2, we performed an ubiquitin assay with extract from HEK293T cells. The cells were transiently cotransfected with ADAR2 or a mutant where either single or both PPxY motifs in ADAR2 were mutated and a further construct expressing WWP2. Poly-ubiquitination of ADAR2 was detected in extracts from cells cotransfected with constructs expressing wild-type ADAR2 and WWP2 proteins but there was a decrease in poly-ubiquitination with both the ADAR2^NH~2~--PPxY^ and ADAR2^COOH--PPxY^ single mutants. Only in the presence of ADAR2^--PPxY^ was there a complete loss of poly-ubiquitination ([Figure 7A](#f7){ref-type="fig"}). Poly-ubiquitination was also observed in the absence of V5-UBQ as there was sufficient endogenous ubiquitin in the cell extract ([Figure 7A](#f7){ref-type="fig"}, lane 1).

To demonstrate that the proteosome affected the stability of ADAR2, a time course was performed in the presence of the proteosome inhibitor MG132 ([Figure 7B](#f7){ref-type="fig"}). An increase in the level of ADAR2 was observed; however, there was not a reciprocal increase in the levels of the ADAR2^--PPxY^ mutant. This mutant could no longer bind WWP2 so the protein level could no longer be regulated by the proteasome, therefore, the proteosome inhibitor had no effect on its stability.

To determine if an increase in stability of ADAR2 would affect its localization, immunofluorescence was performed in *Pin1*^+/+^ and *Pin1*^−/−^ MEF cells and were transiently transfected with ADAR2^--PPxY^. A cytoplasmic accumulation of ADAR2^--PPxY^ was evident ([Figure 7C](#f7){ref-type="fig"}). Previously it had been difficult to observe an accumulation of ADAR2 within the cytoplasm as the protein was being degraded by WWP2 ([Figure 3A](#f3){ref-type="fig"}). However, as the binding of WWP2 is impaired in the ADAR2^--PPxY^ mutant, the cytoplasmic accumulation is obvious. Nuclear and cytoplasmic fractionation was performed with the ADAR2^--PPxY^ mutant in MEF wild-type and *Pin1*^−/−^ cells and the results were quantified ([Figure 7D and E](#f7){ref-type="fig"}). It is clear that in the absence of Pin1 and if WWP2 cannot bind to ADAR2, there is a cytoplasmic accumulation of ADAR2 that is not observed under normal conditions.

Discussion
==========

These data illustrate the complex regulation of ADAR2 by two proteins with opposing effects; Pin1 is a positive regulator of ADAR2 whereas WWP2 can bind and cause degradation. Pin1 and WWP2 regulate other protein such as the large subunit of RNA pol II and this regulation is conserved from yeast to mammals ([@b43]).

When ADAR2 is phosphorylated at the amino-terminus, it becomes a substrate for the phosphorylation-dependent prolyl-isomerase Pin1. The enzymatic activity of Pin1 is required for the localization and stability of ADAR2 in the nucleus. In the absence of Pin1, ADAR2 is unstable and is present in the cytoplasm. It can then interact with WWP2, an E3 ligase that results in its poly-ubiquitination and subsequent degradation by the proteasome ([Figure 8](#f8){ref-type="fig"}). One direct consequence of this is a reduction in editing of the Q/R site and R/G sites in *GluR2* transcripts. The presence of unedited GluR2^Q^ subunit can have dramatic downstream effects as it can increase the trafficking of GluR2 subunit to the synapse as well as increasing the permeability of AMPA receptors to calcium ions.

The function of Pin1 is to isomerize a specific proline from the *cis* to *trans* conformation or *vice versa* ([@b32]; [@b45]). Most biological processes require proline to be in the *trans* conformation; however, when the protein is translated the choice in conformation is dependent on the surrounding amino acids. If there is a pool of ADAR2 that is not phosphorylated and therefore not a Pin1 substrate, then this protein may not be fully active. This probably does occur as ADAR2 is expressed in various mammalian cell lines such as HeLa and SH-SY5Y but is not very active and for efficient editing of transcripts, additional ADAR2 must be transfected. There may be sufficient Pin1 present but the kinase required for the phosphorylation of the Pin1-binding site may be limited. This may explain the pool of inactive ADAR2 that has been observed as it may require phosphorylation and subsequent Pin1 activity. For example in the undifferentiated NT2 cell line, ADAR2 is well expressed; however, it requires differentiation of the NT2 to neuronal cells for efficient editing of *GluR2* Q/R; this occurs without any major change in ADAR2 expression ([@b17]). The authors of that study proposed that a post-translational regulatory mechanism is involved.

In the absence of Pin1, ADAR2 mislocalizes to the cytoplasm. It is difficult to detect ADAR2 as it is poly-ubiquitinated by WWP2 in the cytoplasm and degraded. Only when WWP2 is unable to bind to ADAR2 is high level of cytoplasmic accumulation of ADAR2 observed ([Figure 7](#f7){ref-type="fig"}). There are two binding sites for WWP2 on the ADAR2 protein. The site in the amino-terminus of ADAR2 appears to be more important for WWP2 interaction than the site in the deaminase domain despite the deaminase site being more conserved. The crystal structure for the deaminase domain of ADAR2 has been solved ([@b26]) and the PPLY amino acids are on the outside of the protein opposite to the region that has been proposed to interact with the RNA ([Supplementary Figure S6](#S1){ref-type="supplementary-material"}). Therefore, these amino acids are easily accessible to WWP2.

The finding that ADAR2 is regulated by Pin1 and WWP2 opens up new avenues of research. Under normal conditions, ADAR2 is present within the nucleolus ([@b7]; [@b38]). However, once a substrate is transfected into the cell, it relocates to the nucleus and editing can occur. One key factor that is missing is the kinase that phosphorylates ADAR2 and instigates this complex regulation. Also, we would predict from our results both with the ADAR2 triple mutant ([Figure 1](#f1){ref-type="fig"}) and with ADAR2^P33A^ ([Figure 4](#f4){ref-type="fig"}) that Thr32 is phosphorylated and that this is a key phosphorylation event. Pin1 interaction requires the binding of ADAR2 to dsRNA; however, we do not know whether the kinase phosphorylates ADAR2 in the bound or unbound state. Also, we do not know what happens after RNA editing has occurred. Is ADAR2 then a substrate for a phosphatase that results in its relocation to the nucleolus or is it exported and degraded? In the absence of Pin1, ADAR2 mislocalizes to the cytoplasm where it is a substrate for WWP2; however, the molecular mechanism underlying this mislocalization is unknown. It is important to elucidate how these various factors regulate the activity of ADAR2 as this will subsequently impinge on the properties of the AMPA receptor.

This report of post-translational regulation of ADAR2 reveals how ADAR2 is highly coordinated and regulated within the cell as this ultimately controls the calcium permeability and assembly of AMPA receptors. This opposing regulation by Pin1 and WWP2 is very analogous to that of the large subunit of yeast RNA polymerase (pol) II where the yeast orthologue of Pin1; *ESS1* binds to the C-terminal domain and positively regulates RNA pol II transcription whereas *RSP5*; a HECT-type E3 ligase similar to WWP2 mediates its ubiquitination and degradation ([@b43]). This regulation of RNA pol II large subunit by Pin1 and WWP2 is also conserved in mammals ([@b19]; [@b44]). Therefore, we propose that these two proteins with opposing effects can act coordinately in the regulation and stability of other key cellular proteins.

The interaction of ADAR2 with Pin1 may explain why the Q/R site is edited to 100% in neurons. Pin1 is a key regulator of many proteins and processes within the cell; however, it is itself regulated by phosphorylation, which inhibits its activity ([@b23]; [@b18]). We hypothesize that as Pin1 is the hub of a regulatory network and that transient ischaemia or other insults lead to reduction in Pin1 activity. A decrease in ADAR2 activity would then ensue with a subsequent reduction in editing at the Q/R site in *GluR2* transcripts. This would result in increased calcium permeability of AMPA receptors that could have major effects depending on the region of the brain and the presence of calcium-binding proteins or calcium pumps within the particular neuron. If calcium-binding proteins are low as in the CA1 pyramidal neurons, then this could lead to neuronal cell death ([@b21]). Therefore, we propose 100% editing of Q/R in the *GluR2* transcript is a 'quality control\' measure that reflects a healthy neuron. Data from mice support this hypothesis as when the edited GluR2^R^ isoform has been knocked-in, the mice have no apparent phenotype despite a lack of the unedited isoform ([@b15]). An explanation why rats expressing GluR2^R^ are resistant to forebrain ischaemia in the vulnerable CA1 pyramidal neurons could be that the regulatory network from Pin1 to ADAR2 editing the *GluR2* Q/R site has been disrupted ([@b20]). Other experiments are required to rigorously test this hypothesis; however, if it is correct it will facilitate devising treatments to limit the neuronal damage associated with forebrain ischaemia.

Materials and methods
=====================

A more detailed Materials and methods section is provided in [Supplementary Data](#S1){ref-type="supplementary-material"}.

Mass spectrometry of ADAR2
--------------------------

A measure of 1 μg of ADAR2 with FLAG and tetra-histidine epitope tags was purified after overexpression in *P. pastoris* as previously described ([@b33]). The purified protein was denatured in Novex LDS sample buffer plus 10 mM DTT at 65°C for 30 min and alkylated with 50 mM 4-vinylpyridine for 15 min at room temperature. The protein was separated by SDS--PAGE on a 4--12% MOPS NUPAGE gel, stained with colloidal Coomasie and digested with trypsin (5 μg/ml) in 50 mM ammonium bicarbonate. The phosphopeptides were enriched with PHOS-select resin (Sigma) and analysed on a 4700 TOF--TOF mass spectrometer as described previously ([@b3]).

ADAR2 mutagenesis
-----------------

The pcD3 construct expressing FLAG--ADAR2 has been previously described ([@b11]). All mutations were generated with the QuickChange mutagenesis strategy (Stratagene, La Jolla, CA) and were sequenced to verify the intended mutations.

S^26^ to A: 5′-ctggacaacgtggcccccaaggatggc-3′

T^32^ to A: 5′-tcccccaaggatggcagcgcacctgggcctgg-3′

S^26/31^ to A: 5′-gtcccccaaggatggcgccacacctgggcctggcga-3′

S^26/31^/T^32^ to A: 5′-ggacaacgtggctcccaaggatggcgccgcacctgggcctg-3′

P^27^ to A: 5′-ctggacaacgtgtcc[g]{.ul}ccaaggatggcagcaca-3′

P^33^ to A: 5′-cccaaggatggcagcaca[g]{.ul}ctgggcctggcgagggctct-3′

ADAR2 was subcloned into pEGFP-C3 with the oligonucleotides:

*Eco*RI-ADAR2 5′-ccggaattctgatggatatagaagatgaagaaaacatgagt-3′

ADAR2-*Sal*I (antisense) 5′-ccggtcgacctcagggcgtgagtgagaactggtcctgctc-3′.

WWP2 cloning and mutagenesis
----------------------------

WWP2 was cloned by PCR amplification of cDNA clone IMAGE 100008816 (Gene Service) in the expression vector pENTR221 with the oligonucleotides 5′-*GGGGACAAGTTTGTACAAAAAAGCAGGCTCA*ATG**GACTACAAGGACGACGATGACAAA**GCATCTGCCAGCTCTAGCCGGGCA-3′ and antisense 5′-*GGGGACCACTTTGTACAAGAAAGCTGGGTC*CTA[**ATGGTGATGGTGATGGTG**]{.ul}CTCCTGTCCAAAGCCTTCGGTCTC-3′ for subsequent gateway cloning (Invitrogen). Similarly, N- and C-terminal truncations of hADAR2 were constructed by PCR amplification of hADAR2 cDNA into the pGEM T-Easy vector with the oligonucleotides. 5′-*GGGGACAAGTTTGTACAAAAAAGCAGGCT*ATG**GACTACAAGGACGACGATGACAAA**GATATAGAAGATGAAGAAAAC-3′ and antisense 5′-*GGGGACCACTTTGTACAAGAAAGCTGGGT*CTA[**ATGGTGATGGTGATGGTG**]{.ul}TGGCGTCTGATCCAAGTCCAA-3′ primers were used to produce a construct encoding only the N-terminal portion of hADAR2.

To produce a construct encoding the C-terminal portion of hADAR2 with the oligonucleotides 5′-*GGGGACAAGTTTGTACAAAAAAGCAGGCT*ATG**GACTACAAGGACGACGATGACAAA**TTGCACTTGGATCAGACGCCA-3′ and antisense 5′-*GGGGACCACTTTGTACAAGAAAGCTGGGT*CTA[**ATGGTGATGGTGATGGTG**]{.ul}GGGCGTGAGTGAGAACTGGTC-3′ were used. All primers were designed to incorporate 5′ FLAG (bold) and 3′ HIS epitope tags (underlined) at either end of the respective ORF, as well as the *att* recombination sites required for gateway cloning (italics). The purified PCR products were cloned by site-specific recombination into the donor vector pDONR221 to generate an entry clone. The entry clone was used in a second site-specific recombination reaction with the modified destination vector pcD3 (origin pcDNA3) to generate the expression clone (following the standard protocol, as described by Invitrogen).

To generate FLAG--ADAR2 NH~2~^--PPxY^ (PPFY to AAFA) and FLAG--ADAR2 COOH~2~^--PPxY^ (PPLY to AALA) the following oligonucleotides were used:

FLAG--ADAR2^NH~2~--PPxY^ 5′-gacaaggcggcagcatttgccgtgggctcc-3′ and for FLAG--ADAR2^COOH--PPxY^ 5′-gaggacctggcagctctcgccaccctcaac-3′

Immunoblot analysis, immunoprecipitation and GST pull down
----------------------------------------------------------

Expression and purification of the GST-tagged proteins were performed as described ([@b4]). Immunoprecipitation was performed as described ([@b35]). Immunoblot analysis was performed with primary antibodies: mouse α-FLAG 1:3000 (Sigma), mouse α-HA 1:1000 (Sigma), mouse α-MPM-2 1:1000 (Upstate Cell Signaling) ([@b5]) mouse α-Pin1 1:500 (G-8) (Santa Cruz Biotechnology, Santa Cruz, CA) rabbit α-ADAR2 1:1000 (Sigma), mouse α-GST 1:5000 dilution (Amersham Pharmacia), overnight at 4°C, followed by an 1-h incubation with the appropriate secondary antibody (Dako).

Ubiquitination assay and proteasome-mediated degradation analysis
-----------------------------------------------------------------

Cells were cotransfected with the indicated constructs at the following ratios: FLAG--ADAR2 and FLAG--ADAR2^--PPxY^ 1 μg, FLAG--WWP2 and FLAG--WWP2 (C/A) 4 μg, V5-UBA 1 μg. After 24 h, cells were harvested and lysed under denaturing conditions, and ubiquitinated proteins were purified with Ni^2+^-NTA agarose beads (QIAGEN) as described previously ([@b34]). The cells in [Figure 7A](#f7){ref-type="fig"} were incubated for 4.5 h with 20 μM MG132 (Calbiochem), 20 μM MG5 (Sigma) prior to lysis.

Cell lines, transfection conditions and RNA extraction
------------------------------------------------------

MEF cells were cultured in a Hypoxic incubator, 10% CO~2~, 3% O~2~ (Thermo Scientific HeraCell 150i) ([@b28]). Total RNA was extracted from cells with Trizol reagent (Invitrogen) and treated with Turbo DNA-free DNAseI beads (Ambion). cDNA synthesis was performed with random-hexamer primers. PCR of the *GluR2 B13* minigene was performed with primer, 5′-atggaagagaaacacaaagt-3′ that anneals to exon 11 and antisense primer 5′-gaatgataggaaccttctgc-3′ that anneals to intron 11 ([@b13]). PCRs conditions were 94°C for 3 min, followed by 28 cycles of: 94°C for 30 s, 54°C for 30 s, 72°C for 45 s and 72°C for 7 min. For endogenous *GluR2* transcript, 1 μg of DNAse-treated total RNA was used for cDNA synthesis and RT--PCR was performed with Superscript™III One step RT--PCR System (Invitrogen), was performed with primer, 5′-atggaagagaaacacaaagt-3′ and the antisense primer 5′-ttccctttggacttccgcac-3′ that anneals to exon 13.

RNAi knockdown
--------------

siRNA or pSUPER transfections were performed in HeLa and SH-SY5S cells with Lipofectamine 2000 reagent (Invitrogen). Both siRNA against *GAPDH* and smart Pool of siRNAs against *Pin1* (LPIN1, Dharmacon Thermo Scientific) were added to a final concentration of 100 nM. The pSUPER*Pin1* and pSUPER*LacZ* were used as siRNA controls as previously described ([@b35]).

Indirect immunofluorescence
---------------------------

Cells were plated on sterile cover-slips in six-well plates at 2.5 × 10^5^ cells/well and grown overnight before transient transfection of expression constructs with Fugene 6 transfection reagent (Roche). Indirect immunofluorescence was performed as previously ([@b2]).

Preparation of cytoplasmic and nuclear extracts
-----------------------------------------------

Cytoplasmic and nuclear fractionation was performed with ProteoExtract Subcellular Proteome Extraction Kit (Merck) according to the manufacturer\'s instructions. Quantification of cytoplasmic and nuclear fractionation was performed with the IMAGEQUANT/TL (GE Heathcare Life Science).
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![The amino-terminus of ADAR2 harbours a Pin1-binding site. (**A**) The anti-MPM-2 antibody recognizes potential Pin1 sites in ADAR2 purified after overexpression in *P. pastoris*. Immunoblot analysis with anti-MPM-2 antibody of anti-FLAG immunoprecipitates from lysates of HEK293T cells transfected with FLAG-tagged hADAR2, ADAR2^S26A/S31A^, ADAR2^S26A/S31A/T32A^, ADAR2^S26A^, ADAR2^T32A^ or pcD3. The minor band in the lane with pcD3 is contamination from the neighbouring lane. ADAR input visualized with anti-FLAG antibody, lower panel. (**B**) Purified ADAR2 binds *in vitro* to Pin1 immobilized on beads. (Upper left panel) Immunoblot analysis with anti-FLAG antibody of the binding of FLAG-tagged ADAR2, ADAR2^S26A^, ADAR2^S26A/S31A/T32A^, ADAR2^Δ4--72^ bound to GST--Pin1 or GST on glutathione beads. (Lower panel) GST input visualized with anti-GST antibody. (Right panel) Purified ADAR proteins stained with Coomassie. (**C**) Binding of purified ADAR2 to Pin1 depends on phosphorylation of Pin1 sites on ADAR2. λ phosphatase treatment of lysate from HEK293T cells transfected with ADAR2 for 0 (−), 2 h (+), 3 h (++) prior to incubation with GST--Pin1. Immunoblot analysis of ADAR2 with anti-FLAG antibody. Middle and lower panels are input loading controls. (**D**) Pin1 binds to ADAR2 in HEK293T cells. Coimmunoprecipitation of ADAR2 and Pin1 performed with anti-FLAG antibody on HEK293T cell lysate cotransfected with HA--Pin1 and either FLAG-tagged ADAR2, ADAR2^Δ4--72^, ADAR2^RRM1--2^, ADAR2^S26A/S31A/T32A^ or pcD3. HA--Pin1 was detected with anti-HA antibody. Asterisks represent IgG light chain. (Lower panel) Immunoblot of input proteins with anti-FLAG antibody. (**E**) Endogenous Pin1 detected with anti-Pin1 antibody after immunoprecipitation with anti-FLAG antibody from cell lysates of HEK293T cells transfected with FLAG-tagged ADAR2, ADAR2^S26A/S31A/T32A^, ADAR2^Δ4--72^, ADAR2^RRM1--2^ or pcD3. (Lower panel) Immunoblot of input proteins detected with anti-FLAG antibody. Asterisks represent IgG light chain.](emboj2011303f1){#f1}

![Pin1 is required for efficient editing at the *GluR2* Q/R site. (**A**) DNA sequence chromatograph of the RT--PCR product of the region encompassing the Q/R site (arrow) encoded by the *GluR2 B13* minigene transiently cotransfected with ADAR2 (2 μg) in HeLa cells, editing is 100% (left chromatograph). Editing of the Q/R site drops to 53% when an siRNA specific for *Pin1* is cotransfected together with plasmids encoding both ADAR2 and the *GluR2 B13* minigene (middle chromatograph). Editing is 100% at the *GluR2* Q/R site when a control siRNA is cotransfected (right chromatograph). Immunoblot analysis of cell lysate from HeLa cells with either anti-Pin1 or anti-tubulin antibodies (right panel). (**B**) (Left panel) Sequencing chromatogram of editing by endogenous ADAR2 at the Q/R site of RT--PCR product pools from the *GluR2 B13* minigene transcript that has been transiently transfected into HeLa cells. Arrows indicate Q/R editing site in all panels. Immunoblot analysis with anti-Pin1 antibody of HeLa cell extracts that have been cotransfected with GFP in the presence of either *Pin1*-specific siRNA, no siRNA or HA--Pin1 construct (0.5 μg). Proteins are detected with anti-Pin1 antibody and anti-GFP antibody as a loading control (right panel). (**C**) Chromatograph of editing of endogenous *GluR2* transcript at the Q/R site in neuroblastoma SH-SY5Y cells transfected with ADAR2 (2 μg). Editing is 100% at the Q/R site (left chromatograph). A decrease in editing is observed when an siRNA specific for *Pin1* was cotransfected (middle chromatograph). A control siRNA does not affect editing when transfected (right chromatograph). Arrows indicate the Q/R site. Cell lysates of SH-SY5Y cells were analysed by immunoblot with either anti-Pin1 or anti-tubulin (right panel). (**D**) Chromatograph of editing at the Q/R site of *GluR2 B13* minigene transcript in *Pin1*^−/−^ MEF cells transfected with ADAR2 (2 μg). Editing increased to 100% when *Pin1*^−/−^ MEF cells were cotransfected with either 0.5 or 1 μg of a construct expressing Pin1. An arrow marks the Q/R editing site in all the chromatographs.](emboj2011303f2){#f2}

![Pin1 is required for nuclear localization of ADAR2. (**A**) ADAR2 is mislocalized from the nucleus to the cytoplasm in *Pin1*^−/−^ MEF cells. GFP--ADAR2 immunofluorescence in *Pin1*^+/+^ and *Pin1*^−/−^ MEF cells cotransfected with *GluR2 B13* minigene and GFP--ADAR2. DAPI staining of nuclei (i, iv), GFP fluorescence of cell (ii, v) and merged (iii, vi). (**B**) Nuclear localization of ADAR2 is restored in *Pin1*^−/−^ MEF cells by transfection of HA--Pin1. GFP--ADAR2 (green) direct and HA--Pin1 (red) indirect immunofluorescence detection in *Pin1*^−/−^ MEF cells cotransfected with *GluR2 B13* minigene and (ii) GFP--ADAR2 (green) and (iii) HA--Pin (red). (i) DAPI staining of nuclei. (iv) Merge of all three images. (**C**) Nuclear localization of ADAR2 depends on catalytic activity of Pin1. GFP--ADAR2 (green) and HA--Pin1^S67E^ (red) in *Pin1*^−/−^ MEF cells cotransfected with *GluR2 B13* minigene and (ii) GFP--ADAR2 (green) and (iii) HA--Pin1^S67E^ (red). (i) DAPI staining of nuclei. (iv) Merge of all three images. All photographs were taken at the same exposure. Scale bar, 10 μm. (**D**) Nucleo-cytoplasmic fractionation. Immunoblot analysis with anti-FLAG antibody of nuclear and cytoplasmic fractions of *Pin1*^−/−^ MEF cells transfected with FLAG--ADAR2 (lanes 1 and 2). Pin1 was cotransfected with FLAG--ADAR2 in *Pin1*^−/−^ MEF cells (lanes 3 and 4). HA--Pin1^S67E^ was cotransfected in *Pin1*^−/−^ MEF cells (lanes 5 and 6). (Lower panel) Immunoblot of fractionated *Pin1*^−/−^ MEF cells with tubulin as a marker for cytoplasmic fraction and HP1α for nuclear fraction.](emboj2011303f3){#f3}

![Proline 33 of ADAR2 is required for the Pin1 effect on ADAR2 nuclear localization. (**A**) Normal localization of ADAR2 and Pin1. Immunofluorescence of HeLa cells cotransfected with *GluR2 B13* minigene, FLAG--ADAR2 and HA--Pin1 stained with (i) DAPI, (ii) anti-HA--Pin1 (green), (iii) anti-FLAG--ADAR2 (red), (iv) Merge of DAP1 and FLAG and (v) merge of all three images. (**B**) Nuclear localization of ADAR2 depends on Proline 33. Immunofluorescence of HeLa cells cotransfected with *GluR2 B13* minigene, FLAG--ADAR2^P33A^ and HA--Pin1 stained with (i) DAPI, (ii) anti-HA--Pin1 (green), (iii) anti-FLAG--ADAR2^P33A^ (red), (iv) Merge of DAP1 and FLAG and (v) merge of all three images. All photographs were taken at the same exposure. Scale bar, 10 μm. (**C**) Nucleo-cytoplasmic fractionation of wild-type and ADAR^P27A^ and ADAR2^P33A^ mutants. Immunoblot analysis with anti-FLAG antibody of nuclear and cytoplasmic fractions of HeLa cells transfected with FLAG--ADAR2 (lanes 1 and 2), ADAR^P27A^ (lanes 3 and 4), ADAR2^P33A^ (lanes 5 and 6). (Lower panels) Immunoblot of fractionated HeLa cells with tubulin as a cytoplasmic marker and HP1α as a nuclear marker.](emboj2011303f4){#f4}

![Pin1 contributes to stability of ADAR2 protein. (**A**) Knockdown of *Pin1* in HeLa cells destabilizes ADAR2 in a cycloheximide time course. HeLa cells were transfected with either pSuper *LacZ* or pSuper *Pin1*. Cycloheximide (50 μg/μl) was added to both and a time course from 0 to 8 h was performed. Cell lysates were analysed by immunoblot and the antibodies used were anti-ADAR2 (top panel), anti-tubulin as a loading control (middle panel) and Pin1 (bottom panel). (**B**) Quantification of (**A**). (**C**) *Pin1* knockdown destabilization of FLAG--ADAR2 in SH-SY5Y neuroblastoma cells. SH-SY5Y cells were cotransfected with FLAG-tagged ADAR2 and a control siRNA or *Pin1*-specific siRNA. Cycloheximide (50 μg/μl) was added to both and a time course from 0 to 8 h was performed. Cell lysates were analysed by immunoblot and the antibodies used were anti-FLAG (top panel), anti-Pin1 (middle panel) and GFP as loading control (bottom panel). (**D**) ADAR2 mutant in the Pin1-binding site is less stable. SH-SY5Y neuroblastoma cells were transfected with FLAG-tagged ADAR2^S26A/S31A/T32A^ and cycloheximide (50 μg/μl) was added and a time course was performed from 0 to 8 h. Cell lysates were analysed by immunoblot and the antibodies used were anti-FLAG (top panel), anti-Pin1 (middle panel) and GFP as loading control (bottom panel).](emboj2011303f5){#f5}

![WWP2 interacts with ADAR2. (**A**) Coimmunoprecipitation of ADAR2 and WWP2 performed with anti-FLAG antibody in HEK293T cell lysate cotransfected with FLAG--ADAR2 and c-myc--WWP2 or pcD3 empty vector. FLAG--ADAR2 was detected with FLAG antibody. WWP2 input visualized with anti-c-myc antibody (bottom panel). (**B**) Endogenous WWP2 detected with anti-WWP2 antibody after immunoprecipitation with anti-FLAG antibody from lysates of HEK293T cells transfected with FLAG-tagged ADAR2, ADAR2^2--305^, ADAR2^298--701^, ADAR2^Δ4--72^ or pcD3. Immunoblot of input proteins detected with anti-FLAG antibody (bottom panel). (**C**) Immunoprecipitation of FLAG--ADAR2 and mutants with mutations in the amino, carboxyl binding site for WWP2 or a combination of both was performed with anti-FLAG antibody in HEK293 cells. Endogenous WWP2 detected with anti-WWP2 antibody. (Lower panel) Immunoblot of input proteins detected with anti-FLAG antibody. (**D**) Immunoblot analysis with anti-FLAG antibody of lysates from HeLa cells cotransfected with FLAG--ADAR2 and increasing amount of FLAG--WWP2 (0.5, 1, 2.5 μg) (upper panel) and this experiment was repeated with the mutant ADAR2^PPxY^ that is unable to bind to WWP2 (lower panel). The efficiency of transfection was normalized to GFP expression. GFP input visualized with anti-GFP antibody is shown below both panels.](emboj2011303f6){#f6}

![WWP2 is required for ADAR2 ubiquitination and subsequent degradation in the cytoplasm. (**A**) *In vivo* ubiquitination assays. FLAG--ADAR2--His, FLAG--WWP2--His and V5-UBQ were transfected in HEK293T cells followed by purification of ubiquitination complexes from lysates with Ni^2+^-NTA. In lane 1, cotransfection was with FLAG--ADAR2--His, FLAG--WWP2--His. Lane 2, cotransfection was with FLAG--ADAR2--His, FLAG--WWP2--His and V5-UBQ. Lane 3, cotransfection of FLAG--ADAR2 NH~2~^--PPxY^--His, FLAG--WWP2--His and V5-UBQ. Lane 4, cotransfection of FLAG--ADAR2 COOH^--PPxY^--His, FLAG--WWP2--His and V5-UBQ. Lane 5, cotransfection of FLAG--ADAR2^--PPxY^--His (double mutant), FLAG--WWP2--His and V5-UBQ. Lane 6 is the same as lane 5 without the addition of V5-UBQ and is the negative control. (Middle panel) Immunoblot of input proteins detected with anti-FLAG antibody. (Lower panel) Immunoblot of V5-UBQ present in the purified complex detected with anti-V5 antibody. (**B**) Immunoblot at 24 h following transfection of FLAG--ADAR2 and FLAG--ADAR2^--PPxY^ with 20 μM MG132 to inhibit protein degradation. The proteasomal inhibitor MG132 was added to both and a time course from 0 to 4.5 h was performed in HeLa cells. Cell lysates were normalized to GFP levels (lower panel). (**C**) Immunofluorescence of *Pin1*^+/+^and *Pin1*^−/−^ MEF cells cotransfected with *GluR2* and FLAG--ADAR2^--PPxY^ (double mutant). (i) DAPI staining of nuclei. (ii) Anti-FLAG--ADAR2^--PPxY^ (red). (iii) Merge of DAP1 and FLAG. Scale bar, 10 μm. All photographs were taken at the same exposure. (**D**) Nuclear and cytoplasmic fractionation of FLAG--ADAR2^--PPxY^ in *Pin1*^+/+^and *Pin1*^−/−^ MEF cells. (Lower panels) Immunoblot of fractionated MEF cells with tubulin as a cytoplasmic marker and HP1α as a nuclear marker. (**E**) Quantification of (**D**).](emboj2011303f7){#f7}

![Schematic representation of the regulation of ADAR2 by Pin1 and WWP2. ADAR2 can exist as a monomer in the nucleus and has sequences at its amino-terminus that inhibit enzymatic activity ([@b25]). However, ADAR2 can be phosphorylated by an unknown kinase either when it is free or bound to dsRNA. ADAR2 is a substrate for Pin1 once it is bound to dsRNA and the active form of ADAR2 is a dimer ([@b9]; [@b31]; [@b40]). The mechanism of dimer formation is still unclear. After RNA editing has occurred, we do not know the fate of ADAR2. However, in the absence of Pin1, ADAR2 mislocalizes to the cytoplasm where it is poly-ubiquitinated by WWP2 and is degraded by the proteasome.](emboj2011303f8){#f8}
